humoral immunity

Humoral immunity begins when naive B cells recognize antigen via their B cell receptor (surface IgM/IgD). For T-dependent antigens (mainly protein antigens), B cells process and present antigen via MHC II to CD4+ helper T cells (Th2 predominantly), which provide CD40L-CD40 costimulation and cytokines (IL-4, IL-5, IL-21) driving B cell proliferation, class switching (isotype switching), somatic hypermutation, and affinity maturation in germinal centers of lymph nodes/spleen. This produces plasma cells secreting high-affinity antibodies (IgG, IgA, IgE) and memory B cells. T-independent antigens (e.g., polysaccharide capsules, LPS) can activate B cells directly via crosslinking of BCRs without T cell help, typically producing lower-affinity IgM without memory formation—clinically relevant because young children (<2 years) respond poorly to polysaccharide vaccines (e.g., unconjugated pneumococcal vaccine) due to immature T-independent responses, hence conjugate vaccines (e.g., Hib, PCV13) link polysaccharide to protein carriers to recruit T cell help. Antibodies function via neutralization, opsonization (enhancing phagocytosis via Fc receptors), complement activation (classical pathway via IgG/IgM), and antibody-dependent cellular cytotoxicity. Clinical significance includes: humoral immunodeficiencies (X-linked agammaglobulinemia/Bruton's - BTK mutation, absent B cells; Common Variable Immunodeficiency; IgA deficiency; Hyper-IgM syndrome from CD40L mutation) predisposing to recurrent sinopulmonary infections and encapsulated organism infections. Vaccination strategies exploit humoral immunity (subunit, conjugate, toxoid vaccines). Understanding germinal center reactions is key for board questions on immunodeficiencies and vaccine mechanisms.